Lotvin Alan reported grant involving 135,000 derivative units of PROKIDNEY CORP. at $0.00 for $0 on May 28, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed May 29, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
135,000Director stock option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
135,000Direct
Trade date
May 28, 2026Grant
Filed
May 29, 2026, 4:07 PM ET1-day reporting delay
Accession
0001193125-26-248262Code A · Transaction 94756
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

PROK price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
PROK · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago 0%1w ago −4.4%1d ago −1.1%
Returns since7d −1.6%30d 0%90d180d1y

Footnotes in full

F1: These options were granted under the Issuer's non-employee director compensation policy. F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.